CORRESP 1 filename1.htm CORRESP

AEGLEA BIOTHERAPEUTICS, INC.

805 Las Cimas Parkway

Suite 100

Austin, TX 78746

June 4, 2021

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

 

Attention:   

Alan Campbell

Office of Life Sciences

        Re:   

Aeglea BioTherapeutics, Inc.

Registration Statement on Form S-3

Filed May 28, 2021

File No. 333-256614

Via EDGAR - Acceleration Request

 

            Requested Date:    June 8, 2021
            Requested Time:    4:00 p.m. Eastern Time

Ladies and Gentlemen:

Aeglea BioTherapeutics, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.

The Registrant hereby authorizes Robert A. Freedman or Ryan Mitteness, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.

Sincerely,
AEGLEA BIOTHERAPEUTICS, INC.
By:   /s/ Anthony Quinn
  Anthony Quinn
  Chief Executive Officer

 

cc:

Robert A. Freedman, Esq.

Ryan Mitteness, Esq.

Fenwick & West LLP